Our portfolio

An original biologic is a complex product generated from biotechnological processes within living cells. A biosimilar is similar to the original biologic but only appears on the market after the reference product is no longer protected by a patent. A biosimilar is "similar" to the original in terms of efficacy, safety and quality, as well as in the clinical sense; very slight variations can occur, however, because biosimilars are produced by living systems (cells).

They are equally effective, as shown by repeated clinical trials and as certified by Swissmedic. Because of their biological origin, biosimilars may vary slightly from one production run to the next, but any variations remain within very precise limits and in no way influence the products’ safety, efficacy and quality.

According to the Swiss Federal Office of Public Health (FOPH), biosimilars must generally cost at least 25% less than their reference products when they are marketed (with some exceptions). Biosimilars are reimbursed by insurance companies in exactly the same way as their reference products.

The significant price difference between biosimilars and originals leads to significant savings and enhances the financial efficiency of our healthcare system. This means that more people can benefit from modern therapies at a reasonable price.

For more information on our products, feel free to reach out to us or visit the Swissmedic website. You may also find useful information on our partner companies' websites.